Connect your AI

LivaNova LIVN Translation and other

Translation and other at other companies

GE HealthCare TechnologiesGEHC

——

Segments

By segment

Cardiopulmonary-$7.25M-161%

Neuromodulation$0—

Other financials

Income statement

Revenue$362.3M+14.3%

Gross profit$243.7M+12.7%

Operating income$41.5M-14.7%

Net income$22.3M+107%

EPS (diluted)$0.40+107%

Balance sheet

Cash & equivalents$539.7M-26.9%

Total debt$340.9M-49.7%

Total equity$1.2B+17.1%

Total assets$2.5B-1.7%

Cash flow

Operating cash flow$15.2M-36.5%

CapEx$14.3M+32.4%

Free cash flow$926.0K-93.0%

Valuation

Market cap$4.32B+62.8%

Profitability

Gross margin67.5%-0.5pp

Operating margin13.4%+0.8pp

Net margin-16.1%-18.0pp

FCF margin11.2%-0.2pp

Returns & leverage

Return on equity-17.6%-19.5pp

Debt / equity0.3×-0.4×

Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's translation and other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is LivaNova's translation and other?: LivaNova (LIVN) reported translation and other of -$7.25M in Q1 2026.
How has LivaNova's translation and other changed year-over-year?: LivaNova's translation and other decreased by 160.9% year-over-year, from $11.91M to -$7.25M.